Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model

DOI: 10.1080/2162402X.2018.1532763

Keywords: ONCOS-102, Pembrolizumab, melanoma, NOG, immunogenic cell death, PD-1 inhibitor, antitumor, cancer vaccine, oncolytic adenovirus

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text